Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
3,902,461
-
Share change
-
+197,272
-
Total reported value
-
$7,907,971
-
Put/Call ratio
-
43%
-
Price per share
-
$2.23
-
Number of holders
-
32
-
Value change
-
+$19,411
-
Number of buys
-
10
-
Number of sells
-
17
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2019
As of 31 Dec 2019,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,902,461 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, Cresset Asset Management, LLC, TSP Capital Management Group, LLC, BlackRock Inc., DIMENSIONAL FUND ADVISORS LP, ACADIAN ASSET MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
33
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.